iTeos Therapeutics (ITOS) AI Stock Analysis

• Market Cap: $241.39M
• Dividend Yield: N/A
• Average Volume (3M): 344.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: 177.89%
• EPS Growth: -10.95%
• Country: US
• Employees: 173
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -3.49
• Shares Outstanding: 38,194,340
• 10 Day Avg. Volume: 292,934
• 30 Day Avg. Volume: 344,864
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 7.51
• Price to Cash Flow (P/CF): 12.00
• P/FCF Ratio: 12.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $23.20
• Price Target Upside: 267.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

iTeos Therapeutics faces significant financial challenges, including negative profit margins and cash flows, which are the most critical factors impacting its stock score. The technical analysis indicates bearish momentum and valuation metrics reflect ongoing losses. However, corporate events provide some optimism with future data presentations and collaborations potentially enhancing market positioning.

Positive Factors

Clinical Trials

Potential for ITOS upside is seen in response to large clinical updates from the company’s anti-TIGIT belrestotug therapies in NSCLC and SCCHN.

Financial Stability

The company holds cash and cash equivalents of approximately $655 million, deemed sufficient to fund its operations and upcoming studies.

Negative Factors

Financial Performance

The company reported no revenue and a net loss, with projections indicating continued losses in the future.

Market Performance

The stock is down -11% vs. XBI -4% YTD, and it may be difficult for investors to assign more credit to the TIGIT program unless safety improves.

Safety Concerns

Interim data from a study showed a high occurrence of treatment-related adverse events, leading to amendments in the study protocol to address safety concerns.

iTeos Therapeutics Business Overview & Revenue Model

Company Description

iTeos Therapeutics (ITOS) is a biotechnology company focused on the discovery and development of innovative immuno-oncology treatments. The company operates within the pharmaceutical and healthcare sectors, aiming to harness the power of the immune system to provide transformative therapies for cancer patients. iTeos Therapeutics is dedicated to advancing a pipeline of drug candidates designed to improve and extend the lives of individuals battling cancer.

How the Company Makes Money

iTeos Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include potential milestone payments and royalties from partnerships and collaborations with larger pharmaceutical companies. A significant partnership with GlaxoSmithKline (GSK) involves the development and commercialization of EOS-448, an anti-TIGIT antibody, which provides upfront payments, potential milestone payments, and future royalties on sales. Additionally, the company may generate revenue through licensing agreements and strategic collaborations, leveraging its expertise in immuno-oncology to expand its financial opportunities.

iTeos Therapeutics Financial Statement Overview

Summary

iTeos Therapeutics faces profitability and cash generation challenges, with negative profit margins and cash flows. Despite a strong balance sheet with low leverage, operational inefficiencies and volatile revenue growth pose significant risks.

Income Statement

iTeos Therapeutics has experienced significant revenue fluctuations, with a decline from 2021 to 2023 and an uptick in 2024. The gross profit margin remains strong at 100% due to zero cost of goods sold, but the net profit margin is negative, reflecting the substantial net losses. EBIT and EBITDA margins are also severely negative, indicating operational challenges. Revenue growth is volatile, posing a risk to stability.

Balance Sheet

The company maintains a strong equity base with a high equity ratio, indicating financial stability. The debt-to-equity ratio is low, reflecting minimal leverage risk. However, the return on equity has been impacted negatively by recent losses. Overall, the balance sheet demonstrates resilience but is pressured by operational losses.

Cash Flow

Free cash flow remains negative, consistent with the operating losses, but shows a slight improvement in 2024. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation from operations. The cash flow statement indicates a reliance on financing activities to offset operating cash deficits.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.00M	12.60M	267.63M	344.77M	0.00
	Gross Profit
35.00M	11.70M	266.82M	344.16M	-535.00K
	EBIT
-159.53M	-151.10M	126.32M	244.90M	-45.24M
	EBITDA
-153.09M	-151.10M	148.38M	257.08M	-37.84M
	Net Income Common Stockholders
-134.41M	-112.64M	96.65M	214.52M	-38.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
494.65M	531.92M	613.16M	848.54M	336.33M
	Total Assets
686.98M	667.59M	754.99M	884.71M	344.56M
	Total Debt
5.10M	6.06M	4.67M	5.34M	0.00
	Net Debt
-137.03M	-245.12M	-280.13M	-843.20M	-336.33M
	Total Liabilities
96.68M	92.36M	91.66M	331.89M	21.36M
	Stockholders Equity
590.29M	575.23M	663.33M	552.82M	323.20M
Cash Flow		Free Cash Flow
-99.81M	-106.72M	-112.13M	511.96M	-25.53M
	Operating Cash Flow
-98.18M	-103.76M	-111.19M	513.14M	-25.18M
	Investing Cash Flow
-131.15M	72.66M	-446.06M	-1.24M	-377.00K
	Financing Cash Flow
122.24M	1.11M	1.98M	3.66M	340.34M

iTeos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITOS, the sentiment is Negative. The current price of 6.32 is below the 20-day moving average (MA) of 6.92, below the 50-day MA of 7.24, and below the 200-day MA of 10.75, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 29.68 is Positive, neither overbought nor oversold. The STOCH value of 15.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITOS.

iTeos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDTX	51 Neutral	$245.25M	―	-222.36%	―	-86.28%	-476.70%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
ITOS	48 Neutral	$241.39M	―	-23.06%	―	177.89%	-10.95%
MNPR	48 Neutral	$246.11M	―	-51.42%	―	―	-35.23%
ABEO	47 Neutral	$241.21M	―	-216.57%	―	-100.00%	30.33%
AVIR	46 Neutral	$250.59M	―	-33.88%	―	―	-22.66%
DSGN	32 Underperform	$238.97M	―	-19.08%	―	―	26.63%

iTeos Therapeutics Corporate Events

iTeos Therapeutics Plans 2025 Data Presentation on Therapies

iTeos Therapeutics announced plans to present new data from its clinical trials and research pipeline in 2025, focusing on its TIGIT:PD-1 therapies. The company aims to enhance its market opportunities and improve the safety profile of its therapies, with a financial runway secured through 2027. Key data readouts are anticipated from ongoing trials, including GALAXIES Lung-201 and GALAXIES H&N-202, while collaborations with GSK are expected to further bolster iTeos’ position in the immuno-oncology landscape.